Zhitong Finance App News, Clover Bio-B (02197.HK) announced positive preliminary data from a phase II clinical trial conducted in the elderly population in Australia. The test was used to evaluate SCB1022 (rSV+hMPv) and SCB-1033 (rSV+hMPv+pIV3) protein vaccine candidates. The antigen is a trimeric subunit vaccine antigen based on stabilized F protein (PrEF) before fusion, using Trimer-Tag (protein trimer) vaccine development platform validated by Clover Biology.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.